Integrating Blood Pressure Control With Multi-Class Kidney Protective Agents in Diabetic Kidney Disease

Diabetic kidney disease (DKD) remains a leading cause of chronic kidney disease progression and cardiovascular morbidity and mortality. Blood pressure (BP) control is a cornerstone of risk reduction in DKD, yet its management has become increasingly complex with the emergence of multi-class kidney-protective agents. Traditionally centered on renin-angiotensin-aldosterone system (RAAS) blockade with additional antihypertensive agents, contemporary treatment now incorporates sodium-glucose cotransporter-2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists, and incretin-based therapies. Recent trials evaluating intensive systolic BP targets have demonstrated cardiovascular benefit in selected high-risk populations; however, the balance between benefit and kidney-related harm remains relevant in DKD. While RAAS blockade provides meaningful BP reduction and renoprotection, SGLT2 inhibitors, finerenone, and incretin-based therapies confer modest but clinically relevant BP lowering alongside substantial cardiorenal benefits through complementary mechanisms. Although these agents are not primarily used for antihypertensive intensification, their meaningful BP-lowering effects can influence overall BP control in routine practice. Although combination therapy appears biologically plausible and may enhance overall cardio-kidney-metabolic protection, definitive evidence supporting optimal sequencing, parallel initiation, or superiority in hard clinical outcomes remains limited. A pragmatic, individualized approach integrating disease-modifying therapies with conventional antihypertensive agents is therefore warranted. Future dedicated trials are needed to clarify optimal integration strategies to achieve safe BP control while maximizing long-term kidney and cardiovascular protection in DKD.